Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Published:2012-11-07 Issue:1 Volume:19 Page:215-224
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Ryan Charles J.,Rosenthal Mark,Ng Siobhan,Alumkal Joshi,Picus Joel,Gravis Gwenaëlle,Fizazi Karim,Forget Frédéric,Machiels Jean-Pascal,Srinivas Sandy,Zhu Min,Tang Rui,Oliner Kelly S.,Jiang Yizhou,Loh Elwyn,Dubey Sarita,Gerritsen Winald R.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of Molecular Detection Technologies for MET in Lung Cancer;Cancers;2023-05-26

2. Drug discovery in Rheumatoid Arthritis-induced Osteonecrosis of the Femoral Head;2023-03-30

3. A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib;Clinical Lung Cancer;2022-06

4. Mesenchymal Epithelial Transition (MET): A Key Player in Chemotherapy Resistance and an Emerging Target for Potentiating Cancer Immunotherapy;Current Cancer Drug Targets;2022-04

5. Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials;Cureus;2022-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP